<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00415064</url>
  </required_header>
  <id_info>
    <org_study_id>Perifosine 127</org_study_id>
    <nct_id>NCT00415064</nct_id>
  </id_info>
  <brief_title>Phase I Study of Perifosine + Lenalidomide and Dexamethasone for Patients With Multiple Myeloma</brief_title>
  <official_title>An Open-Label Phase I Study of the Safety of Perifosine in Combination With Lenalidomide and Dexamethasone for Patients With Relapsed or Refractory Multiple Myeloma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AEterna Zentaris</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AEterna Zentaris</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a phase I study of perifosine in combination with lenalidomide and dexamethasone for
      patients with relapsed or refractory multiple myeloma. The current protocol will enroll
      patients with relapsed or refractory multiple myeloma requiring second or third line therapy.
      Six patients each will be treated with at one of 4 dose levels in a phase 1 study. All
      patients will receive perifosine, lenalidomide and dexamethasone of each 28 day cycle. The
      doses of perifosine and lenalidomide will be varied in each group. The dose of dexamethasone
      will remain constant.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a phase I study of perifosine in combination with lenalidomide and dexamethasone for
      patients with relapsed or refractory multiple myeloma. All patients will receive lenalidomide
      daily for days 1 to 21 of each 28 day cycle. Perifosine will be given daily qhs with food.
      Dexamethasone will be given on days 1-4, 9-12 and 17-20 for 4 cycles. After 4 cycles
      dexamethasone will be given only on days 1-4. Four dose levels will be studied:

        1. Perifosine 50 mg, lenalidomide 15 mg and dexamethasone 20 mg

        2. Perifosine 50 mg, lenalidomide 25 mg and dexamethasone 20 mg

        3. Perifosine 100 mg, lenalidomide 15 mg and dexamethasone 20 mg

        4. Perifosine 100 mg, lenalidomide 25 mg and dexamethasone 20 mg

      Six patients will be enrolled at each dose level until the maximum tolerated dose (MTD) is
      reached. Six additional patients will be treated at the MTD.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2006</start_date>
  <completion_date type="Actual">July 2012</completion_date>
  <primary_completion_date type="Actual">July 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Adverse Events</measure>
    <time_frame>Every cycle</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinically significant changes in the patient's physical examination, vital signs, and clinical laboratory results</measure>
    <time_frame>Every 12 weeks</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">32</enrollment>
  <condition>Multiple Myeloma</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Perifosine</intervention_name>
    <description>Perifosine given in either 50 mg or 100 mg / day</description>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lenalidomide</intervention_name>
    <description>Lenalidomide given in either 15 or 25 mg / day</description>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamethasone</intervention_name>
    <description>Dexamethasone given in 20 mg / day</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subject was previously diagnosed with multiple myeloma based on standard diagnostic
             criteria, as follows.

          -  Major criteria:

               1. Plasmacytomas on tissue biopsy.

               2. Bone marrow plasmacytosis (&gt; 30% plasma cells).

               3. Monoclonal immunoglobulin spike on serum electrophoresis immunoglobulin G (IgG)
                  &gt;3.5 g/dL or immunoglobulin A (IgA) &gt; 2.0 g/dL; kappa or lambda light chain
                  excretion &gt; 1 g/day on 24 hour urine protein electrophoresis.

          -  Patients must have relapsed or refractory disease (refractory is defined as
             progression during treatment or within 60 days after the completion of treatment)
             requiring 2nd or 3rd line therapy

          -  Patients refractory to a combination of lenalidomide and dexamethasone will not be
             eligible. Patients may have received lenalidomide and/or dexamethasone

        Exclusion Criteria:

          -  Renal insufficiency (serum creatinine levels &gt; 3 mg/dL)..

          -  History of allergic reactions attributed to compounds of similar chemical or biologic
             composition to perifosine (miltefosine or edelfosine).

          -  Known hypersensitivity to thalidomide
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andrzej J Jakubowiak, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>University of Michigan</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Jakubowiak AJ, Richardson PG, Zimmerman T, Alsina M, Kaufman JL, Kandarpa M, Kraftson S, Ross CW, Harvey C, Hideshima T, Sportelli P, Poradosu E, Gardner L, Giusti K, Anderson KC. Perifosine plus lenalidomide and dexamethasone in relapsed and relapsed/refractory multiple myeloma: a Phase I Multiple Myeloma Research Consortium study. Br J Haematol. 2012 Aug;158(4):472-80. doi: 10.1111/j.1365-2141.2012.09173.x. Epub 2012 May 29.</citation>
    <PMID>22640031</PMID>
  </results_reference>
  <verification_date>November 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 20, 2006</study_first_submitted>
  <study_first_submitted_qc>December 20, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 22, 2006</study_first_posted>
  <last_update_submitted>July 3, 2012</last_update_submitted>
  <last_update_submitted_qc>July 3, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 6, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Multiple Myeloma</keyword>
  <keyword>Perifosine</keyword>
  <keyword>Lenalidomide</keyword>
  <keyword>Dexamethasone</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone acetate</mesh_term>
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Lenalidomide</mesh_term>
    <mesh_term>Thalidomide</mesh_term>
    <mesh_term>BB 1101</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

